---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-034175"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:13:02.532559+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MindMed reports $273.7M cash, advances MM120 Phase 3 trials in GAD and MDD

## Summary
- Cash and equivalents $273.7M at Dec 31, 2024 vs $99.7M a year ago; raised ~$250M in 2024.
- Q4 2024 R&D expense $21.8M (from $11.5M); full-year $65.3M (from $52.1M).
- Phase 3 Voyage (GAD) dosing initiated; topline data expected 1H 2026.
- Phase 3 Panorama (GAD) initiated Q1 2025; data expected 2H 2026.
- On track to start Phase 3 Emerge (MDD) 1H 2025; topline data 2H 2026.

## SEC filing metadata
- accession: 0000950170-25-034175
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017025034175/0000950170-25-034175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017025034175/mnmd-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-034175
- JSON: https://secwatch.observer/filing/0000950170-25-034175.json
- Plain text: https://secwatch.observer/filing/0000950170-25-034175.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.